Dear O 'Dear , the second approved test in the UK Global Access Diagnostics is Roche's Covid-19 test that was booted from Germany , they got in under Emergency use authorisation by FDA then into the UK , won't be long till Roche's will be booted from UK also with that poor sensitivity, Anteotec's RAT test looks the best test fit for purpose , compare to Roche that spent $12 billion on R&D , Anteotech has done very well indeed .
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit
www.roche.com.
Roche, Abbott COVID Antigen Tests Just So-So in Real-World Data— "Unsatisfactory" for screening asymptomatic people, say German lab professionalsby
John Gever, Contributing Writer, MedPage Today August 9, 2021
Sensitivities for the antigen tests were especially low -- under 40% -- when the individuals had no comorbidities, were asymptomatic (just 23% for the Abbott test and barely 30% for Roche's), or had previously recovered from COVID.
Among 2,215 "all-comers" tested at a German diagnostics lab, with 338 ultimately showing positive results with PCR testing, Roche's SD Biosensor and Abbott's Panbio rapid antigen tests showed overall sensitivities of 60.4% and 56.8%, respectively, reported Christoph Wertenauer, of Synlab GmbH in Augsburg and the University of Heidelberg in Mannheim, and colleagues.
https://www.medpagetoday.com/infectiousdisease/covid19/93961March 2020
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care
https://diagnostics.roche.com/globa...symptomatic-and-asymptomatic-individuals.html
